Sanofi earnings beat but sales lower in 3rd-qtr

31 October 2019
sanofi-paris-big

French pharma major Sanofi (Euronext: SAN) saw its share price dip a fraction by mid-morning, after posting lower third-quarter 2019 sales, hit by a fall in revenue at its primary care business and a drop in its vaccines business.

Net sales for the quarter were 9,499 million euros ($10.56 billion), up 1.1% on a reported basis, down 1.1% at constant exchange rates (CER) and up 0.5% at CER/CS..Sanofi Genzyme sales increased 19.5% driven by continued strong uptake of Dupixent (dupilumab). Vaccines sales fell 9.8% reflecting anticipated weighting of US flu vaccines supply towards fourth quarter. CHC sales up 0.4%, impacted by Zantac (ranitidine) voluntary recall, non-core divestments and increased regulatory requirements. Primary Care sales declined 12.7% at CER/CS due to lower sales in Diabetes and Established Products.

Third-quarter 2019 business net income increased 4.3% to 2,399 million euros and 0.2% at CER, which was above expectations. Business earnings per share (EPS) were stable at CER at 1.92 euros. IFRS EPS was 1.49 euros, down 18.6% reflecting the capital gain on the European generics divestment in third-quarter 2018.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical